Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/4572
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lindgren, P | - |
dc.contributor.author | Buxton, MJ | - |
dc.contributor.author | Kahan, T | - |
dc.contributor.author | Poulter, NR | - |
dc.contributor.author | Dahlof, B | - |
dc.contributor.author | Sever, PS | - |
dc.contributor.author | Wedel, H | - |
dc.contributor.author | Jönsson, B | - |
dc.date.accessioned | 2010-10-29T16:01:10Z | - |
dc.date.available | 2010-10-29T16:01:10Z | - |
dc.date.issued | 2007 | - |
dc.identifier.citation | Heart, 94(2): e4, 4th October 2007 | en_US |
dc.identifier.issn | 1355-6037 | - |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/4572 | - |
dc.description | Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society. Internal or personal use of this material is permitted. However, permission to reprint/republish this material must be obtained from the Publisher. | en_US |
dc.description.abstract | Objective: To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden. Design: A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects. Setting: Primary care. Patients: Patients with moderate hypertension and three or more additional risk factors. Interventions: Amlodipine 5–10 mg with perindopril 4–8 mg added as needed or atenolol 50–100 mg with bendroflumethiazide 1.25–2.5 mg and potassium added as needed Main outcome measures: Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained. Results: In the UK, the cost to avoid one cardiovascular event or procedure would be €18 965, and the cost to gain one quality-adjusted life-year would be €21 875. The corresponding figures for Sweden were €13 210 and €16 856. Conclusions: Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare’s Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol-based regimen in the population studied. | en_US |
dc.description.sponsorship | The study was supported by the principal funding source, Pfizer, New York, USA. | en_US |
dc.language.iso | en | en_US |
dc.publisher | British Medical Journals Publishing Group Ltd & British Cardiovascular Society | en_US |
dc.subject | Hypertension | en_US |
dc.subject | Primary prevention | en_US |
dc.subject | Amlodipine | en_US |
dc.subject | Atenolol | en_US |
dc.subject | Cost-effectiveness | en_US |
dc.title | Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen | en_US |
dc.type | Research Paper | en_US |
dc.identifier.doi | http://dx.doi.org/10.1136/hrt.2007.127217 | - |
Appears in Collections: | Community Health and Public Health Health Economics Research Group (HERG) Dept of Health Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 108.91 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.